November 4, 2024
Breakthrough T1D, Formerly JDRF, Celebrates Progress in Cell Therapy Research on the Path to Type 1 Diabetes Cures as Vertex Announces Pivotal Trial for VX-880
October 31, 2024
Breakthrough T1D, Formerly JDRF, Expresses Disappointment in FDA Advisory Committee Recommendation Regarding Sotagliflozin
October 29, 2024
Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine
September 20, 2024
A Statement from Breakthrough T1D, formerly JDRF, on the Federal Trade Commission’s Insulin Prices Lawsuit
September 19, 2024
Breakthrough T1D Mourns the Passing of Former IBOD Member Preetish Nijhawan
September 11, 2024
Breakthrough T1D CEO Dr. Aaron J. Kowalski to Co-Chair EASD Symposium on How Devices Help Those with Diabetes
September 9, 2024
Breakthrough T1D and Integrated Nanotherapeutics Collaborate to Advance Development of an Immune Tolerizing Therapeutic to Treat Type 1 Diabetes
August 20, 2024
Type 1 Diabetes Advocate and Breakthrough T1D Volunteer, Joshua Davis, leads Pledge of Allegiance on Night Two of Democratic National Convention
August 19, 2024
InSphero, Breakthrough T1D and Université libre de Bruxelles Collaborate to Find New Cures for Type 1 Diabetes
August 15, 2024
